Replies to post #16599 on Momenta Pharmaceuticals, Inc. (MNTA)

[Boing x 2]

DewDillegence,

Thank you for the ariticle.

Throw in these two

"Anti-Inflammatory Therapeutics Market
Anti-Inflammatory Therapeutics Market Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Inflammation is the mechanism of innate immunity, which seeks to eliminate the cause of injury, clear dead and necrotic cells ... Published Date:
Sep 2015 Price:
$4740(SU)

Biosimilars Market
Biosimilars Market Biosimilars or follow-on-biologics are highly similar versions of reference biologics derived from living organisms such as plants and animals. The development of biosimilars and validation with reference biologics play a significant role in the commercialization of biosimilars. Economic pricing of ..."

and we have some pocket change to go after.

Boing X 2

[indigokid]

Always good news when the market is large and growing and you have a ptoential product with 10x the potency of current products (M254).

Next question is who does MNTA decide to partner with on M254? One of the 3 big players: Shire (formerly Baxter/Baxalta)), CSL (JV partner already), or Grifols??? Or someone else?